Gemcitabine and radiotherapy in the treatment of uterine cervical cancer patients at Phramongkutklao Hospital.

Abstract

OBJECTIVES:

To determine response, complication and survival of uterine cervical cancer patients treated with concurrent gemcitabine radiotherapy.

MATERIAL AND METHOD:

A retrospective review of medical records of 41 patients with uterine cervical cancer patients, stage IIB and above treated with concurrent gemcitabine radiotherapy from August 2000 to August 2003.

RESULTS:

At 6 and 12 months of follow up, the complete response rate was 75.6% and 65.9%. The cumulative probability of survival at 6 and 12 months after treatment was 0.93 and 0.85. The main complications were mild hematologic and nonhematologic toxicities.

CONCLUSION:

Concurrent gemcitabine radiotherapy provided a satisfactory response in patients with uterine cervical cancer with mild toxicity. Long term follow up data is necessary to determine the recurrent rate of this regimen.

• Authors: Phanida Jarruwale, Yawana Tanapat, Pote Aimpun
• Journal: Journal of the Medical Association of Thailand = Chotmaihet thangphaet (J Med Assoc Thai) Vol. 88 Suppl 3 Pg. S19-24 (Nov 2005) ISSN: 0125-2208 [Print] Thailand
• PMID: 16858940 (Publication Type: Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Deoxycytidine
• Gemcitabine

Topics

• Adult
• Aged
• Antimetabolites, Antineoplastic (therapeutic use)
• Carcinoma (drug therapy, mortality, radiotherapy)
• Combined Modality Therapy
• Deoxycytidine (analogs & derivatives, therapeutic use)
• Female
• Humans
• Middle Aged
• Retrospective Studies
• Survival Rate
• Thailand
• Treatment Outcome
• Uterine Cervical Neoplasms (drug therapy, mortality, radiotherapy)
• Gemcitabine